Photopheresis

What is Photopheresis?

Photopheresis, also known as extracorporeal photoimmunotherapy (ECP), is a form of apheresis therapy. First introduced for the treatment of cutaneous T-cell lymphoma (CTCL), it has since been evaluated in studies and randomized trials as a potential treatment for autoimmune diseases, solid organ transplant rejection, and Graft-versus-Host Disease after stem cell transplant..

How is Photopheresis Done?

The procedure consists of placing an IV line into the patient's arm. Peripheral blood is drawn into the instrument where the white cells or buffy coat and a small amount of plasma are isolated and mixed with UVADEX, a drug that can be activated by light. The buffy coat is exposed to ultraviolet light (UVA) to activate the drug and then returned to the patient. The entire procedure takes about four hours. Side effects are minimal and may include nausea and sunlight sensitivity.

Why Photopheresis?

The precise mode of action of ECP is incompletely defined at present, but it is believed that multiple mechanisms are most likely producing the therapeutic effect. One mechanism involves the cross-linking of the DNA in the T-cells disrupting their metabolic/proliferative functions. It is also believed that the photo-damaged cells may induce suppressor T-cells to recognize and eliminate the malignant or autosensitive T-cell clones in an anti-tumor immune response.

IBMT is the lone photopheresis center in Indiana. Patients with CTCL, organ rejection or Graft vs. Host Disease can now be treated close to home in a personalized, convenient setting. A call to 1.800.361.0016 is all that is required to refer for a consultation. Questions? If so, please contact us!

For further information on Photopheresis please see the Therakos website (www.therakos.com)